
Telix at EANM 2025
Join Telix at EANM in Barcelona, to learn more about how we are delivering on the promise of precision medicine through targeted radiation.
The program features a record 28 company-related abstract presentations, showcasing our late-stage and next generation development programs and innovations in MedTech.
On Sunday 5th October at 13:15 in room 116, Telix will bring together expert speakers to discuss the journey “From Pan-Tumor Innovation to Theranostic Precision – FAP and CAIX Case Studies“.
The sponsored symposium will be chaired by Prof. Antoine Italiano, with presentations from Dr. Yuriko Mori, Prof. Dr. Richard P Baum, Prof. Dr. Daniela Oprea-Lager and Dr. Christina Suárez.
Visit booth #78 to explore opportunities for collaboration with Illuccix® (kit for the preparation of gallium-68 gozetotide injection) Telix’s commercial PSMA-PET imaging agent in Europe, our industry-leading theranostic pipeline and medical technologies, including the SENSEI® miniature drop-in gamma probe, QDOSE® dosimetry software and artificial intelligence (AI).
Congress details
Barcelona International Convention Center
Plaça de Willy Brandt, 11-14,
Sant Martí, 08019 Barcelona, Spain
4th-8th October, 2025
View full congress programme here
From Pan-Tumor Innovation to Theranostic Precision – Fibroblast Activation Protein (FAP) and Carbonic Anhydrase IX (CAIX) Case Studies
A Telix sponsored symposium
Sunday, October 5, 2025 | 13:15 – 14:45 (CEST)
Room 116, CCI Barcelona
View symposium details
Abstract presentations
Presenter: I. Primac, SCK CEN, Mol, Belgium
Abstract #: OP-150
Presenter: L. Papp, Medical University of Vienna, Vienna, Austria
Abstract #: OP-352
Presenter: A. Bilinska, Bern University Hospital, Bern, Switzerland
Abstract #: OP-417
Presenter: Z. Cao, Olivia Newton-John Cancer Research Institute and Austin Health, Heidelberg, Australia
Abstract #: OP-516
Presenter: D. Han, Telix Pharmaceuticals, Sydney, Australia
Abstract #: OP-529
Presenter: S. Kleinendorst, RadboudUMC, Nijmegen, Netherlands
Abstract #: OP-521
Presenter: J. Piulats, Bellvitge Biomedical Research Institute, Barcelona, Spain
Abstract #: OP-674
Presenter: A. Piai, IRCCS Ospedale San Raffaele, Milan, Italy
Abstract #: OP-706
Presenter: J. Pichler, Kepler University Hospital, Linz, Austria
Abstract #: OP-778
Presenter: J. Urena Poch, Rostock University Medical Center, Rostock, Germany
Abstract #: OP-779
Presenter: R. Ladjohounlou, University of Wisconsin, Madison, WI, U.S.
Abstract #: OP-767
Presenter: C. Morgat, CHU Bordeaux, Bordeaux, France
Abstract #: EP-0069
Presenter: A. Ivashkevich, Telix Pharmaceuticals, Melbourne, Australia
Abstract #: EP-0130
Presenter: P. Tually, Spartan First Imaging, Kalgoorlie, Australia
Abstract #: EP-0353
Presenter: S. Rasul, Medical University of Vienna, Vienna, Austria
Abstract #: EP-0528
Presenter: F. Gelardi, IRCCS Ospedale San Raffaele, Milan, Italy
Abstract #: EP-0534
Presenter: J. Pichler, Kepler University Hospital, Linz, Austria
Abstract #: EP-0785
Presenter: Y. Omar, Misr Radiology Center, Cairo, Egypt
Abstract #: EP-0810
Presenter: C. Pain, Monash Biomedical Imaging, Melbourne, Australia
Abstract #: EP-0978
Presenter: N. Kumar, Bern University Hospital, Bern, Switzerland
Abstract #: EPS-013
Presenter: P. Fragoso Costa, University Hospital Essen, University Duisburg-Essen, Essen, Germany
Abstract #: EPS-190
Presenter: A. Bilinska, Bern University Hospital, Bern, Switzerland
Abstract #: EPS-193
Presenter: S. Mdanda, Nuclear Medicine Research Infrastructure (NuMeRI), Pretoria, South Africa
Abstract #: OP-349
Presenter: H. Ndlovu, NuMeRI, Pretoria, South Africa
Abstract #: OP-825
Presenter: S. Martlbauer, University Hospital Dusseldorf, Heinrich-Heine-University Dusseldorf, Dusseldorf, Germany
Abstract #: OP-881
Presenter: M. Qebetu, NuMeRI, Pretoria, South Africa
Abstract #: EP-0942
Presenter: K. Ramonaheng, NuMeRI, Pretoria, South Africa
Abstract #: EP-1116
Presenter: S. Sibiya, NuMeRI, Pretoria, South Africa
Abstract #: EP-1200
Illuccix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix’s first generation PSMA-PET imaging agent, has been approved in multiple markets globally. Telix’s SENSEI® drop-in gamma probe is registered with the Australian Therapeutic Goods Administration (TGA) and with the FDA and has attained a Conformité Européenne (CE) Mark for use in the European Economic Area. Telix’s QDOSE® dosimetry software has received 510(k) clearance from the FDA and is CE-marked and Medical Device Regulation (MDR) certified for clinical use within the European Union (EU). No other Telix product listed above has received a marketing authorization in any jurisdiction.
*Presentation includes information about a Telix-owned or licensed FAP-targeting theranostic candidate without input or support from Telix.